Vaxcyte, Inc.
PCVX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $4,989 | $0 | $0 |
| Gross Profit | $0 | -$4,989 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $209,933 | $194,179 | $148,134 | $133,614 |
| G&A Expenses | $32,447 | $32,040 | $32,659 | $28,555 |
| SG&A Expenses | $32,447 | $32,040 | $32,659 | $28,555 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$4,989 | $0 | $0 |
| Operating Expenses | $242,380 | $221,230 | $180,793 | $162,169 |
| Operating Income | -$242,380 | -$226,219 | -$180,793 | -$162,169 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $29,550 | $59,646 | $40,075 | $25,089 |
| Pre-Tax Income | -$212,830 | -$166,573 | -$140,718 | -$137,080 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$212,830 | -$166,573 | -$140,718 | -$137,080 |
| % Margin | – | – | – | – |
| EPS | -1.56 | -1.22 | -1.04 | -1.12 |
| % Growth | -27.9% | -17.3% | 7.1% | – |
| EPS Diluted | -1.56 | -1.22 | -1.04 | -1.12 |
| Weighted Avg Shares Out | 136,196 | 136,034 | 135,691 | 122,845 |
| Weighted Avg Shares Out Dil | 136,196 | 136,034 | 135,691 | 122,845 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29,259 | $31,073 | $32,935 | $36,458 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,064 | $4,989 | $4,874 | $4,785 |
| EBITDA | -$209,766 | -$161,584 | -$175,919 | -$52,577 |
| % Margin | – | – | – | – |